GSK plc
GSK
View Detailed Chart
50.100USD
-0.700-1.38%
Close 01/28, 16:00（ET）Quotes delayed by 15 min
100.85BMarket Cap
14.14P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.38%
5 Days
+4.22%
1 Month
+2.08%
6 Months
+33.78%
Year to Date
+2.16%
1 Year
+42.74%
View Detailed Chart
TradingKey Stock Score of GSK plc
Currency: USD Updated: 2026-01-28Key Insights
GSK plc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.66.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GSK plc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
GSK plc Highlights
StrengthsRisks
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 96.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 96.66%.
Fairly Valued
The company’s latest PE is 14.14, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 386.95M shares, decreasing 5.73% quarter-over-quarter.
Held by Richard Pzena
Star Investor Richard Pzena holds 8.72K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.27.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
47.658
Target Price
-3.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
GSK plc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GSK plc Info
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Ticker SymbolGSK
CompanyGSK plc
CEOWaterhouse (Deborah)
Websitehttps://www.gsk.com/
Related Instruments
-1.51%
+1.46%
-2.35%
-2.49%
-2.86%
-0.95%
-4.07%
-2.59%
-0.89%
-2.42%
+0.79%
-3.62%
-1.69%
-0.91%
-1.06%
-2.61%
0.00%
-2.42%
-1.30%Popular Symbols
256.440
-1.830 (-0.71%)
191.520
+3.000 (+1.59%)
88094.060
-1006.570 (-1.13%)
279.700
+27.040 (+10.70%)
2935.830
-73.870 (-2.45%)
431.460
+0.560 (+0.13%)
5531.840
+155.240 (+2.89%)
64.522
+1.305 (+2.06%)
1.196
+0.002 (+0.15%)
153.241
-0.136 (-0.09%)
